

Variopeptyl® 3.75



Triptorelin Acetate

Let's defeat
**Breast
Cancer**
together

Variopeptyl 3.75 (Triptorelin Acetate) is increasingly being used for the treatment of breast cancer in women with functioning ovaries. They act by downregulating pituitary GnRH receptors, thereby suppressing the release of luteinising hormone (LH) and follicle stimulating hormone (FSH), which, in turn, reduce the main source of estradiol production in the ovaries. GnRH agonists have been shown to be as effective therapeutically as surgical ovarian ablation perimenopausal women with advanced breast cancer. Treatment with the Variopeptyl 3.75 (Triptorelin Acetate) can reduce the risk of chemotherapy induced premature ovarian insufficiency (POI) in women with early breast cancer.

Ovarian toxicity from chemotherapy may be reduced by diminishing ovarian function during the period of treatments. This can be reversibly achieved by the administration of gonadotropin releasing hormone (GnRH) agonists.

The adverse effects of GnRH agonist including menopausal symptoms, osteoporosis, sexual dysfunction, cardiovascular disease, and loss of neurological function.



Your Health, Our Ambitions

In Situ-Forming Gel Advantages:

- Insignificant amount of injection materials (0.4 ml)
- SC Injection Method
- Removable (in case of Allergic reaction)
- Less Side effects
- Increased Efficacy
- Reduction in number of administration
- Greater Cost Effectiveness



Variopeptyl® 3.75

Triptorelin Acetate

IN THE PALLIATIVE TREATMENT OF ADVANCED PROSTATE CANCER

Cut Testosterone to Low Levels Without Cutting



Prostate Cancer

Triptorelin is the first line hormonal therapy for patients with advanced non-metastatic or metastatic prostate cancer. Variopeptyl® 3.75 mg suppresses the testosterone that causes testosterone-dependent prostate cancer cells to grow. Triptorelin acetate is a GnRHa, which is widely used for the treatment of hormone-dependent conditions in men and women. A chronic administration of GnRHa leads to downregulation of GnRH receptors in the pituitary gland, which results in a complete suppression of luteinizing hormone (LH), follicle-stimulating hormone and gonadal steroids after an initial stimulatory phase (hormonal flare). Usually, within 6 weeks of initiation of Triptorelin acetate therapy, serum testosterone is reduced to near surgically castrated levels. Safety, tolerability and adverse effects Overall, Triptorelin acetate is considered to be a very safe and tolerable drug. The biggest concern with the use of GnRH analogs is the initial stimulatory effect it produces; this is an

issue for all diseases treated using this drug. As a super agonist, when the drug is administered, a sharp, initial increase known as a «flare up» occurs in the serum concentrations of LH, FSH and sex steroids. This can exacerbate the condition at first, before hormone levels drop to postmenopausal/castration levels. Flare up is associated with worsening symptoms of the particular condition being treated. Variopeptyl 3.75 mg is provided in two pre-filled syringes: Syringe A delivers high quality Swiss manufactured Triptorelin acetate 3.75 mg and Syringe B delivers a German made polymeric solution 245mg.

Main Office:

No. 19, Parvin St., Vali-e-Asr Ave.,
Tehran- IRAN P.O. BOX:1966834944

Tel : +98 (21) 24852166

Fax: +98 (21) 24852402

CITM@golrangpi.com

Export@golrangpi.com

